# A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

> **NCT01188031** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
- **DRUG:** NIRAVAM TM 2 mg orally disintegrating tablets, single dose

## Key facts

- **NCT ID:** NCT01188031
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188031, "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01188031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*